Product introduction of Tianjin Pharmaceutical Group Co., Ltd.

Chinese patent medicines are the company’s first pillar industry. In terms of Chinese patent medicine products, the company’s flagship products, Suxiao Jiuxin Pills, Xuefu Zhuyu Capsules and other cardiovascular drugs, have reached a technological level It has advanced levels at home and abroad and currently has strong market competitiveness and brand awareness in this field domestically. Among them, Suxiao Jiuxin Pills are a national secret-level protected traditional Chinese medicine. After years of brand building, "Suxiao Jiuxin" has a high reputation among consumers of cardiovascular system drugs and has high consumer loyalty. In 2009, the basic drug catalog is being adjusted. It is retained in the National Essential Drugs List as an exclusive variety and has a large market development space in the future. The subsidiary Zhongxin Pharmaceutical owns Tianjin Tongrentang (1852), Tianjin Darentang (1914), Tianjin Lerentang (1921), which are in the same line as Beijing Tongrentang, and are known as the "leader of health medicine". "Longshun Rong (1833) has more than 20 dosage forms and nearly 800 registered varieties of products, and has formed a standard medicinal material production base, Zhongxin Pharmaceutical Modern Chinese Medicine Industrial Park, supercritical extraction and dripping pill production base, Seven major bases, including the Traditional Chinese Medicine Oral Solid Preparation Industrial Base, have laid a good foundation for the company's development of proprietary Chinese medicines.

Chemical preparations are the company's second largest industry. The company produces 358 chemical preparations, covering tablets, capsules, water injections, freeze-dried powder injections, granules, infusion preparations and other series. . The chemical preparation drugs produced by the company mainly include vascular drugs such as Shoubishan Indapamine sugar-coated tablets, antiviral drugs such as Adefovir tablets, and antibacterial drugs such as cefdinir. Lisheng Pharmaceutical is Tianjin Pharmaceutical's main subsidiary engaged in the production of chemical preparations. The China Securities Regulatory Commission issued an announcement on December 28, 2009. Tianjin Lisheng Pharmaceutical Co., Ltd.'s initial application was approved. Lisheng Pharmaceutical plans to list on the Shenzhen Stock Exchange this time. 46 million shares were issued, and the total share capital after the issuance was 182 million shares. The listing of Lisheng Pharmaceutical will further enhance the company's capital strength and help expand the market visibility of its products.

The company's chemical raw materials are small in scale, and its main products include GCLE, adefovir dipivoxil, etc. However, due to the great impact of the financial crisis in Europe and the United States and other countries and regions, foreign demand for chemical raw materials has decreased significantly. The company's 2008 Since the beginning of this year, the export of APIs has been greatly affected.

The company's pharmaceutical distribution business is mainly distributed in Tianjin and surrounding areas. Due to its historical background and certain pharmaceutical franchises, it has formed a certain monopoly advantage in the local area. The company mainly intervenes in the field of pharmaceutical distribution through Taiping Group, Hongze Company, Tianjin Pharmaceutical Chain Company and Hebei Dezelong. The four companies have their own business focus. Taiping Group mainly focuses on pure sales to hospitals, and Hongze Company mainly focuses on pure sales to hospitals. Mainly as an exclusive agent, Hebei Dezelong focuses on commercial allocation, and Tianjin Pharmaceutical Chain Company focuses on pharmacy retail. The company's sales targets are mainly large hospitals, supplemented by chain pharmacies, drug wholesale stations and third-party terminal markets. The sales network of the company's pharmaceutical distribution business in Tianjin covers 100% of tertiary hospitals and about 50% of second and tertiary hospitals. It is the pharmaceutical batching enterprise with the widest sales network in Tianjin and has formed a certain monopoly advantage in the local area. In addition to strengthening the company's own drug sales, the company's pharmaceutical distribution can also help obtain more pharmaceutical resources. In the future, the company plans to integrate the sales departments of pharmaceutical distribution companies and various production companies. The breadth and depth of the sales network will be A larger increase will enhance the coordinated development of pharmaceutical production and pharmaceutical circulation. However, with the successive introduction of new medical reform plans, the market competition environment is becoming increasingly fierce. The company's pharmaceutical distribution sector will face competition from pharmaceutical commercial wholesalers represented by Sinopharm Holdings Co., Ltd., which will bring certain challenges to the company's pharmaceutical distribution enterprises. Tianjin has strong pharmaceutical and drug research and development capabilities. It currently has the only national-level drug research institute in the country, the Tianjin Drug Research Institute, 1 national-level enterprise technology center (Zhongxin Pharmaceutical Enterprise Technology Center) and 12 Tianjin municipal-level enterprise technology centers, each All affiliated companies have product and technology research and development institutions to carry out work for the company's product and technology development. It has formed a relatively complete science and technology development system, providing powerful technology for the company's new product development, production process improvement, and product quality improvement. support.